working with MDT

MicroDose seeks both out-license and in-license opportunities as well as strategic collaborations for joint development of products

MicroDose out-licenses its proprietary inhalation, combination oral dosage, and needlefree technologies to strategic partners for collaborative development of innovative products meeting unmet medical needs.

MicroDose also develops products in-house and welcomes the opportunity to work in collaboration with partners, with commercial and marketing expertise, to rapidly bring these products to global markets. To feed our product development vision, MicroDose is looking to in-license compounds and molecules for internal development in its areas of strategic focus.

strategic areas of focus for MicroDose are:

For inhalation products: respiratory diseases and supportive care for respiratory illnesses, such as pulmonary infections. Other priority areas include treatments for pain, diabetes, and pulmonary hypertension, and other candidates where pulmonary delivery can enhance efficacy.

For oral dosage products utilizing our PolyCap™ system, we are interested in combination products that enhance treatment effectiveness in patients. Some of the areas of interest are diabetes, hypertension, and hyperlipidemia.
MicroDose is currently seeking partners for its MetPril™ combination capsule product to treat co-morbidity of diabetes and hypertension and for its inhaled insulin product for diabetes.

To discuss an out-license or collaboration opportunity, or to arrange a meeting or presentation on any of MicroDose’s drug delivery technologies or products, please contact:

Scott Fleming, Sr. Vice President, Sales & Marketing
Tel: 732-355-2114 or email: sfleming@mdtx.com

If you have a molecule or product that you believe MicroDose might be interested in for either purchase or in-license, please contact:

Mike Martin, Vice President, Licensing & Business Development
Tel: 732-355-2117 or email: mmartin@mdtx.com